These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37484840)

  • 1. External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations.
    Silva P; Janjan N; Ramos KS; Udeani G; Zhong L; Ory MG; Smith ML
    Front Med (Lausanne); 2023; 10():1198088. PubMed ID: 37484840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an External Control Arm Using Electronic Health Record-Based Real-World Data to Evaluate the Efficacy of COVID-19 Treatment.
    Jeon JY; Kim MJ; Im YJ; Kim EY; Kim JS; Kwon KT; Hwang JH; Kim JS; Kim MG
    Clin Pharmacol Ther; 2023 Jun; 113(6):1274-1283. PubMed ID: 36861352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer.
    Yin X; Mishra-Kalyan PS; Sridhara R; Stewart MD; Stuart EA; Davi RC
    J Biopharm Stat; 2022 Jan; 32(1):204-218. PubMed ID: 34986069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development.
    Yap TA; Jacobs I; Baumfeld Andre E; Lee LJ; Beaupre D; Azoulay L
    Front Oncol; 2021; 11():695936. PubMed ID: 35070951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-arm oncology trials and the nature of external controls arms.
    Hashmi M; Rassen J; Schneeweiss S
    J Comp Eff Res; 2021 Aug; 10(12):1052-1066. PubMed ID: 34156310
    [No Abstract]   [Full Text] [Related]  

  • 11. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.
    Burcu M; Dreyer NA; Franklin JM; Blum MD; Critchlow CW; Perfetto EM; Zhou W
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1228-1235. PubMed ID: 32162381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of anonymization techniques to create an external control arm for clinical trial data.
    Mehtälä J; Ali M; Miettinen T; Partanen L; Laapas K; Niemelä PT; Khorlo I; Ström S; Kurki S; Vapalahti J; Abdelgawwad K; Leinonen JV
    BMC Med Res Methodol; 2023 Nov; 23(1):258. PubMed ID: 37925415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data.
    Zou KH; Vigna C; Talwai A; Jain R; Galaznik A; Berger ML; Li JZ
    Ther Innov Regul Sci; 2024 May; 58(3):443-455. PubMed ID: 38528279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining external control arms in oncology: A scoping review of applications to date.
    Farah E; Kenney M; Warkentin MT; Cheung WY; Brenner DR
    Cancer Med; 2024 Jul; 13(13):e7447. PubMed ID: 38984669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies.
    Izem R; Buenconsejo J; Davi R; Luan JJ; Tracy L; Gamalo M
    Ther Innov Regul Sci; 2022 Sep; 56(5):704-716. PubMed ID: 35676557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021.
    Wang X; Dormont F; Lorenzato C; Latouche A; Hernandez R; Rouzier R
    J Cancer Policy; 2023 Mar; 35():100403. PubMed ID: 36646208
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.